– Funds will support progression of Aro’s pipeline of Centyrin-siRNA programs, including ABX1100, a novel potential treatment for Pompe Disease. – Christopher Picariello, President, Johnson & Johnson Innovation – JJDC, Inc. named to Board of Directors. November 28, 2023 09:00 AM Eastern Standard Time PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a … Continue reading Aro Biotherapeutics Secures $41.5M Series B Financing

November 14, 2023 06:00 AM Eastern Standard Time HENDERSON, Nev.–(BUSINESS WIRE)–Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation. Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support Zura Bio as … Continue reading Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

– Proceeds to advance the company’s platform and support the progress of multiple in-house discovery and development programs targeting diseases of high unmet medical need – Participating investors include EcoR1 Capital, Novo Holdings, Cormorant Capital, OrbiMed and Third Rock Ventures November 02, 2023 08:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing … Continue reading Terremoto Biosciences Closes $175 Million Series B Financing